drugset
drugset / Trial / NCT06691308

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

NCT06691308 ↗

Phase 0 Not yet recruiting 6 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

Clinical study evaluating the safety and efficacy of WL276 CAR-T cell therapy in CD276 positive recurrent or progressive glioblastoma patients

Timeline

Start
2024-11-12
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject WL276 CAR-T cells Cell therapy 5e+06 cells Other
Subject WL276 CAR-T cells Cell therapy 1e+07 cells Other

Indications

glioblastoma